NCT00550745View on ClinicalTrials.gov

ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

PHASE4CompletedINTERVENTIONAL
Enrollment

11,999

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Zoster Vaccine, Live

single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.

BIOLOGICAL

Comparator: placebo

single 0.65 mL Placebo injection. 6 month treatment period.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00550745 - ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) | Biotech Hunter | Biotech Hunter